These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2530762)

  • 21. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
    J Affect Disord; 1990 Apr; 18(4):289-99. PubMed ID: 2140382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New antidepressants and 5-HT uptake inhibitors.
    Montgomery SA
    Acta Psychiatr Scand Suppl; 1989; 350():107-16. PubMed ID: 2530760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of paroxetine.
    Boyer WF; Feighner JP
    J Clin Psychiatry; 1992 Feb; 53 Suppl():3-6. PubMed ID: 1531819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of paroxetine on the quantitative EEG.
    McClelland GR; Raptopoulos P; Jackson D
    Acta Psychiatr Scand Suppl; 1989; 350():50-2. PubMed ID: 2530790
    [No Abstract]   [Full Text] [Related]  

  • 25. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo.
    Peselow ED; Filippi AM; Goodnick P; Barouche F; Fieve RR
    Psychopharmacol Bull; 1989; 25(2):267-71. PubMed ID: 2532373
    [No Abstract]   [Full Text] [Related]  

  • 26. The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo.
    Peselow ED; Filippi AM; Goodnick P; Barouche F; Fieve RR
    Psychopharmacol Bull; 1989; 25(2):272-6. PubMed ID: 2532374
    [No Abstract]   [Full Text] [Related]  

  • 27. Paroxetine: pharmacokinetic and antidepressant effect in the elderly.
    Lundmark J; Scheel Thomsen I; Fjord-Larsen T; Manniche PM; Mengel H; Møller-Nielsen EM; Pauser H; Wålinder J
    Acta Psychiatr Scand Suppl; 1989; 350():76-80. PubMed ID: 2530794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical profile of paroxetine: a novel selective serotonin reuptake inhibitor (SSRI).
    J Clin Psychiatry; 1992 Feb; 53 Suppl():1-68. PubMed ID: 1531815
    [No Abstract]   [Full Text] [Related]  

  • 29. A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
    Kiev A
    J Clin Psychiatry; 1992 Feb; 53 Suppl():27-9. PubMed ID: 1531818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative lack of cardiotoxicity of paroxetine in animal models.
    Cain CR; Hamilton TC; Norton J; Petersen EN; Poyser RH; Thormählen D
    Acta Psychiatr Scand Suppl; 1989; 350():27-30. PubMed ID: 2530780
    [No Abstract]   [Full Text] [Related]  

  • 31. Paroxetine in the treatment of depression: a comparison with imipramine and placebo.
    Feighner JP; Boyer WF
    J Clin Psychiatry; 1992 Feb; 53 Suppl():44-7. PubMed ID: 1531824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy.
    Peselow ED; Robins CJ; Sanfilipo MP; Block P; Fieve RR
    J Abnorm Psychol; 1992 Aug; 101(3):479-86. PubMed ID: 1386856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paroxetine in major depression: a double-blind trial with imipramine and placebo.
    Cohn JB; Wilcox CS
    J Clin Psychiatry; 1992 Feb; 53 Suppl():52-6. PubMed ID: 1531826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paroxetine in the treatment of depression--a randomized comparison with amitriptyline.
    Laursen AL; Mikkelsen PL; Rasmussen S; le Fèvre Honoré P
    Acta Psychiatr Scand; 1985 Mar; 71(3):249-55. PubMed ID: 3157296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facet theoretic analysis of the Hamilton-D scale.
    Steinmeyer EM; Möller HJ
    J Affect Disord; 1992 May; 25(1):53-61. PubMed ID: 1385599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal dose regimen for paroxetine.
    Dunner DL; Dunbar GC
    J Clin Psychiatry; 1992 Feb; 53 Suppl():21-6. PubMed ID: 1531817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression.
    Rickels K; Amsterdam J; Clary C; Fox I; Schweizer E; Weise C
    J Clin Psychiatry; 1992 Feb; 53 Suppl():30-2. PubMed ID: 1531820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of paroxetine in elderly depressed patients.
    Ghose K
    Acta Psychiatr Scand Suppl; 1989; 350():87-8. PubMed ID: 2530797
    [No Abstract]   [Full Text] [Related]  

  • 40. The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol.
    Cooper SM; Jackson D; Loudon JM; McClelland GR; Raptopoulos P
    Acta Psychiatr Scand Suppl; 1989; 350():53-5. PubMed ID: 2530791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.